Changeflow GovPing Healthcare & Life Sciences Patent Application for Pseudomonas Recombinant ...
Routine Notice Added Final

Patent Application for Pseudomonas Recombinant Protein Expression

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a new patent application, US20260085338A1, detailing a Pseudomonas sp. strain for recombinant protein expression. The application was filed on September 6, 2023, and relates to novel expression systems for biotechnological applications.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a new patent application (US20260085338A1) filed with the USPTO on September 6, 2023. The application describes a Pseudomonas sp. strain engineered for the production of recombinant proteins, specifically utilizing a nucleotide sequence encoding a phi15 RNA polymerase. It also covers plasmids designed for integration or replication within Pseudomonas sp., featuring a phi15 promoter linked to sequences for recombinant protein insertion or expression.

This patent application does not impose any immediate regulatory obligations on companies. However, it signifies potential future intellectual property developments in the biotechnology sector, particularly for entities involved in recombinant protein production. Companies operating in this space should monitor the patent's progress and consider its implications for their own research and development activities and potential licensing needs.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PSEUDOMONAS RECOMBINANT PROTEIN EXPRESSION SYSTEM

Application US20260085338A1 Kind: A1 Mar 26, 2026

Inventors

Rob LAVIGNE, Maarten BOON, Eveline-Marie LAMMENS

Abstract

The invention relates to a Pseudomonas sp. strain for use in the production of a recombinant protein characterised in that said strain comprises a nucleotide sequence encoding a phi15 RNA polymerase. The invention further relates to a plasmid, capable of integrating or replicating in Pseudomonas sp., comprising a phi15 promoter sequence operably linked to a nucleotide comprising one or more restriction sites for the insertion of a nucleotide sequence encoding a recombinant protein, or operably linked to a nucleotide sequence encoding a recombinant protein.

CPC Classifications

C12P 21/00 C12N 9/127 C12N 15/78 C12Y 207/07048 C12N 2830/002

Filing Date

2023-09-06

Application No.

19109298

View original document →

Named provisions

Inventors Abstract CPC Classifications Filing Date Application No.

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 6th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085338A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Biotechnology Research Recombinant Protein Production
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!